Mereo Biopharma Group Plc ADR(MREO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:00 PM ET (Korea 10/28 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.18 | Insider Own | - | Shs Outstand | 159.6M | Perf Week | -1.15% |
| Market Cap | 0.05B | Forward P/E | - | EPS next Y | 51.71% | Insider Trans | - | Shs Float | 159.6M | Perf Month | -21.16% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -0.02 | Inst Own | 35.46% | Short Float | 2.02% | Perf Quarter | -4.83% |
| Income | -0.03B | P/S | - | EPS this Y | -23.64% | Inst Trans | -6.31% | Short Ratio | 0.81 | Perf Half Y | 4.81% |
| Sales | 0.00B | P/B | 1.63 | EPS next 5Y | -9.9% | ROA | -57.62% | Short Interest | 3.23M | Perf YTD | -30% |
| Book/sh | 0.18 | P/C | 1.55 | EPS past 3/5Y | 8.97% 38.96% | ROE | -67.72% | 52W High | -87.69% ($2.37) | Perf Year | -85.41% |
| Cash/sh | 0.19 | P/FCF | - | Sales past 3/5Y | - | ROIC | -97.88% | 52W Low | 45.85% ($0.20) | Perf 3Y | -83.88% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 44.94% | Gross Margin | - | Volatility(W/M) | 5.67% 8.87% | Perf 5Y | -86.37% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.03 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.88 | EPS Q/Q | 52.76% | Profit Margin | - | RSI (14) | 43.35 | Recom | 2.17 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.88 | Sales Q/Q | -100% | SMA20 | -10.87% ($0.33) | Beta | 0.21 | Target Price | $2 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/8/11 | SMA50 | -4.7% ($0.3) | Rel Volume | 0.07 | Prev Close | $0.28 |
| Employees | 39 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -25% -100% | SMA200 | -13.83% ($0.34) | Avg Volume(3M) | 3.99M | Price | $0.29 |
| IPO | 2019/4/24 | Option/Short | Yes/Yes | Trades | 453 | Volume | 291,337 | Change | 6.07% |
🦴 The company is an innovative clinical-stage biotech developing treatments for rare diseases with high unmet medical need, such as hypophosphatasia and rare pulmonary diseases.
Over the past 1 year, on the lower side
88% below its 1-year high.
Traded less than usual. That is 7% of its average volume.
MREO has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -23.6% this year.
Tap to view numbers
Results came in about as expected
Generally in line with estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -86.4%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 35.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #419 of 594 in the industry
Based on market cap of $47M.
IBIO#418 iBio Inc $47M PER - MREO#419 Mereo Biopharma Group Plc ADR $47M PER - 
BMEA#419 Biomea Fusion Inc $47M PER - 
HYPD#421 Hyperion DeFi Inc $46M PER - 
LONA#422 LeonaBio Inc $46M PER - 
FAQ
What kind of company is MREO?
MREO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MREO?
The market cap of MREO is approximately $47M, ranking 4,881 within its sector.
What is the 52-week high and low for MREO?
MREO has recorded a 52-week high of $2.37 and a low of $0.20.
